NEW YORK, Nov. 17, 2017 /PRNewswire/ --
Description
Big changes ahead as Ocrevus nears approval. How will it affect your brand?
Read the full report: https://www.reportlinker.com/p04833573
Oral therapies are replacing interferons as the mainstay Multiple Sclerosis (MS) treatment, but the big news is the pending approval of Roche/Biogen's Ocrevus, a powerful monoclonal antibody for relapsing and progressive MS patients that promises to upend the treatment algorithm.
Get the details in KOL Insight: Multiple Sclerosis.
Based on interviews with 12 US and European KOLs, the report gives you their candid thoughts about 12 marketed therapies and 11 more in the pipeline.
You'll learn what the future holds for interferons, how oral agents are faring, and how pipeline treatments—from sphingosine modulators, to monoclonal antibodies, pharmaceutical-grade biotin, and other novel mechanisms of action—are likely to compete with established therapies.
"Ocrevus has the potential to really change the landscape and, from a patient perspective, sounds pretty easy." EU Key Opinion Leader
- Prof Shiv Saidha, MD, MBBCh. Associate Professor of Neurology, Johns Hopkins Medicine, Baltimore, Maryland, USA.
- Prof Bianca Weinstock-Guttman, MD. Professor of Neurology and Director of the Jacobs Multiple Sclerosis Center for Treatment and Research, University at Buffalo, New York, USA.
- Prof Mark Freedman, MD. Professor of Medicine in the field of Neurology, University of Ottawa and Director of the Multiple Sclerosis Research Unit, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada.
- Prof Gilles Defer, MD. Head of the Department of Neurology, University Hospital of Caen, France.
- Prof Per Soelberg Sørensen, MD. Professor of Neurology, University of Copenhagen and Director of the Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Top Takeaways
- Once approved, Ocrevus will revolutionise MS treatment: Not just the relapsing remitting form but progressive forms as well, KOLs say. What are the most likely indications for Ocrevus, and will it see first-line usage?
- Interferons in decline: More neurologists are prescribing other agents instead, a trend KOLs expect to continue even as interferon use persists in specific indications. What's behind the drop-off in interferon use, and in which patients will doctors continue to prescribe them?
- Next-generation sphingosine modulators may threaten Gilenya: What will these pipeline agents need to show to gain widespread adoption?
- Copaxone still going strong: Considered the safest MS therapy, Copaxone continues to appeal to risk-averse patients. Has the introduction of generic glatiramer acetate had an impact on Copaxone prescribing?
- Future unclear for Zinbryta: Launched into a crowded marked, Biogen/AbbVie's Zinbryta may struggle to find a niche. What advantages and drawbacks do KOLs say will determine the drug's short-term prospects? Which potential competitor looms longer-term?
- Tecfidera use has plateaued: Safety concerns have made neurologists more cautious about using Tecfidera. Do KOLs expect prescriptions to decline or stay the same? Which Tecfidera competitor is benefitting most from the uncertainty?
- KOLs excited about MD 1003: Intrigued by the potential of pharmaceutical-grade biotin, KOLs are calling for larger trials. What are their most pressing questions and concerns? Where do they see MD 1003 entering the treatment algorithm?
- Novel MoAs hold promise: Despite disappointing study results, KOLs are keeping a close eye on Biogen's anti-LINGO-1 mAb, opicinumab. What has them interested, and what do they suggest as next steps for evaluating the drug?
Read the full report: https://www.reportlinker.com/p04833573
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article